Non-CML Myeloproliferative Diseases, An Issue of Hematology/Oncology Clinics of North America
- 1 Edición, Volumen 26-5 - 10 de octubre de 2012
- Última edición
- Autor: Ross Levine
- Idioma: Inglés
Topics include: Clinical Predictors of Outcome in MPNs; Molecular pathogenesis of MPNs; Disordered signaling in MPNs; Role of TET2/ASXL1 in MPN Pathogenesis; Pathogenesis and… Leer más
Descripción
Descripción
Topics include: Clinical Predictors of Outcome in MPNs; Molecular pathogenesis of MPNs; Disordered signaling in MPNs; Role of TET2/ASXL1 in MPN Pathogenesis; Pathogenesis and treatment of systemic mastocytosis; Role of additional novel therapies in MPNs; Role of novel mutations in MPN pathogenesis and outcome; Role of JAK inhibitors in MPN treatment; Animal Models of MPNs; and Role of Germline Genetic Factors in MPN Pathogenesis.
Detalles del producto
Detalles del producto
- Edición: 1
- Última edición
- Volumen: 26-5
- Publicado: 10 de octubre de 2012
- Idioma: Inglés
Sobre el autor
Sobre el autor
RL
Ross Levine
Human Oncology and Pathogenesis Program.
Department of Medicine, Leukemia Service,
Memorial Sloan Kettering Cancer Center,
New York, New York, USA.
Afiliaciones y experiencia
Memorial SloHuman Oncology and Pathogenesis Program.
Department of Medicine, Leukemia Service,
Memorial Sloan Kettering Cancer Center,
New York, New York, USA.an-Kettering Cancer Center